Streetbeat News

Earnings

JRSH

Jerash Holdings (US) reported a decrease in earnings per share (EPS) for Q2, with $0.03 compared to $0.14 year-over-year (YoY). Additionally, the company's sales of $33.36M fell short of the estimated $36.70M.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:06 pm

MBRX

Moleculin Biotech, Inc. has provided a preliminary update on its recent clinical activities and outlined expected near-term milestones for its clinical development pipeline. The update includes progress on various clinical trials and anticipated key events that could influence the company's future direction and investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:06 pm

TOVX

Theriva Biologics (AMEX:TOVX) reported Q3 EPS of $(0.19), surpassing the $(0.38) estimate and marking a 36.67% improvement from last year's $(0.30) per share loss. The company has $31.2M in cash, expected to last until Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:05 pm

ABL

Abacus Life (NASDAQ:ABL) reported a decrease in adjusted EPS to $0.14 in Q3 2023, down from $0.20 YoY. However, sales increased to $21.12M, up from $17.54M YoY, marking a 20.42% rise.

Portfolio Pulse from saritha@benzinga.com

November 13, 2023 | 1:05 pm

MBRX

Moleculin Biotech, Inc. (NASDAQ: MBRX) reported a narrower loss of $(0.19) per share in Q3 compared to $(0.30) per share in the same quarter of the previous year, indicating a 36.67% improvement in earnings.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:04 pm

OCUP

Ocuphire Pharma reported a Q3 EPS of $0.25, a significant improvement from the $(0.22) loss per share a year ago. Sales for the quarter were $11.94M, surpassing the $3.02M estimate.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:03 pm

ATXS

Astria Therapeutics (NASDAQ:ATXS) reported a narrower loss of $(0.63) per share in Q3 compared to $(0.87) per share in the same quarter last year, marking a 27.59% improvement.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:03 pm

IMCC

IM Cannabis reported a decrease in Q3 revenues to C$12.37M from C$14.17M year-over-year, indicating a decline in sales.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:01 pm

VYNE

VYNE Therapeutics reported Q3 adjusted EPS of $(1.59), surpassing the $(1.97) estimate, marking a 19.29% beat and a 36.9% improvement from last year's $(2.52) per share. However, sales declined to $114K from $167K YoY, a 31.74% decrease.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:50 pm

VYNE

VYNE Therapeutics (NASDAQ:VYNE) reported Q3 earnings with an EPS of $-1.75, beating estimates by 11.17% but with a revenue decrease of $53 thousand from the previous year. Last quarter's EPS miss resulted in a 19.3% share price drop the following day.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 12:50 pm